Clik here to view.
Amgen gets rights to Array’s diabetes program
Array BioPharma has granted Amgen exclusive worldwide rights to its small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with...
View ArticleClik here to view.
In conversation with Dr. Erich Mohr
Dr. Erich Mohr enjoyed his time in academia as a neuropsychologist at the U.S. National Institutes of Health and University of Ottawa. But he couldn’t resist the entrepreneurial call when it came...
View ArticleClik here to view.
In conversation with Dr. Simon Pimstone
As CEO of Xenon Pharmaceuticals, Dr. Simon Pimstone and his partners have led the closely held Vancouver company on a journey of developing novel drugs that target genetically defined targets. By...
View ArticleClik here to view.
In conversation with Cheryl Reicin
There’s no bigger booster of life sciences than Cheryl Reicin, who heads the group practice at Torys LLP. American-born, she moved to Torys in 2004 from McDermott Will & Emery of New York, where...
View ArticleClik here to view.
Rodman starts Affymax at market outperform
Rodman & Renshaw has initiated coverage of Affymax (NASDAQ:AFFY) with a “market outperform” rating and $20 price target, pointing out that the company could soon chip away at Amgen’s 20-year...
View ArticleClik here to view.
Roth analyst assumes coverage of ImmunoGen, rates at buy
Roth Capital Partners analyst Bert Hazlett has assumed coverage of ImmunoGen (NASDAQ:IMGN) with a “buy” rating and 12-month price target of $19. The shares were changing hands at $16.60 midway through...
View ArticleClik here to view.
MLV ups Keryx price target to $25 from $15
MLV & Co. has raised its price target on “buy-rated” Keryx Biopharmaceuticals (NASDAQ:KERX) to $25 from $15, citing unprecedented Phase 2 results for the company’s Zerenex drug candidate in the...
View ArticleClik here to view.
In conversation with Bing Yao
Bing Yao As an SVP of AstraZeneca’s (NYSE:AZN) MedImmune unit, Bing Yao heads the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit at MedImmune, leading a team dedicated to...
View ArticleClik here to view.
Roth starts MacroGenics at buy
Roth Capital Partners has initiated of MacroGenics (NASDAQ:MGNX) with a “buy” rating and $28 price target, saying the “era of molecular engineering is upon us.” The stock closed at $20.03 on Friday....
View ArticleClik here to view.
XTL hopes to begin major lupus trial next year
XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE)....
View ArticleClik here to view.
Leerink starts Affimed Therapeutics at outperform
Leerink Partners has launched coverage of Affimed Therapeutics NV (NASDAQ:AFMD) with an “outperform” rating and price target of $14 in one year. The stock closed at $6.30 on Monday. Affimed is an...
View ArticleClik here to view.
Amarantus names Joseph Rubinfeld to its Board
Amarantus BioScience Holdings (OTCQB:AMBS) has appointed Joseph Rubinfeld, a renowned expert in the field of drug development and a co-founder of Amgen, to the board. Joseph Rubinfeld Dr. Rubinfeld...
View ArticleClik here to view.
In conversation with Dr. Isaac Ciechanover
Dr. Isaac Ciechanover As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to...
View ArticleClik here to view.
In conversation with Dr. Simon Pimstone
As CEO of Xenon Pharmaceuticals, Dr. Simon Pimstone and his partners have led the closely held Vancouver company on a journey of developing novel drugs that target genetically defined targets. By...
View ArticleClik here to view.
Knight Therapeutics to collaborate with Medison Biotech
Knight Therapeutics (TSX:GUD) and closely-held Medison Biotech (1995) Ltd. of Israel have entered a strategic collaboration to bring innovative treatments to patients in Canada, Israel and Romania. The...
View ArticleClik here to view.
XTL hopes to begin major lupus trial next year
XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE)....
View ArticleClik here to view.
Axsome Therapeutics names David Marek as CCO
Axsome Therapeutics (NASDAQ:AXSM) has appointed David Marek as chief commercial officer, effective Aug. 31. Mr. Marek joins Axsome from Amgen (NASDAQ:AMGN), where he was most recently VP and general...
View Article
